The incidence of acute myocardial infarction (AMI) in pregnant women increased between 2005 and 2014, according to research published in the American Journal of Cardiology Jan. 25, but that hike was accompanied by decreases in mortality, cost of care and length of stay among expectant mothers.
An extended analysis of the ODYSSEY OUTCOMES trial has confirmed alirocumab, a PCSK9 inhibitor that hit the medical market in 2015, reduces a patient’s total risk of nonfatal and fatal cardiovascular events after an acute coronary syndrome (ACS).
Aspirin offers modest protection against cardiovascular events in primary prevention, but that benefit is at least partially offset by an increase in major bleeding events, according to a meta-analysis published Jan. 22 in JAMA.
Higher concentrations of troponin—even those that were within a “normal range”—signal increased odds of adverse outcomes among outpatients with stable chest pain, suggesting the biomarker test may improve risk stratification and inform management strategies for this common clinical scenario.
Research published in the Journal of the American Heart Association Jan. 13 has concluded administering PCSK9 inhibitors to acute MI patients ahead of ischemia can mitigate the potential negative neurological effects that come with treatment.
Measuring blood levels of vaspin could independently predict major adverse cardiac events (MACE) in patients who have suffered acute myocardial infarction (AMI), according to research published Jan. 16 in the Journal of the American Heart Association, potentially improving early risk stratification in heart attack survivors.
Copayment vouchers for P2Y12 inhibitors modestly improved the likelihood that patients would continue taking the guideline-recommended medications for one year after myocardial infarction, according to a study published in JAMA. However, patients supplied with this financial assistance didn’t see a subsequent improvement in clinical outcomes.
ST-segment elevation myocardial infarction (STEMI) survivors covered by Medicaid have lower rates of revascularization and higher rates of in-hospital mortality than their counterparts with private insurance, according to a study published in Circulation: Cardiovascular Quality and Outcomes.
Sleeping less than six hours a night or experiencing poor-quality rest has been independently linked to an increased risk of subclinical multiterritory atherosclerosis, a team of Spanish researchers reported in the Journal of the American College of Cardiology Jan. 14.
A study published online in the American Journal of Epidemiology Jan. 14 suggests any physical movement, whether it’s short, long, intense or mild, counteracts the negative cardiovascular effects of sitting for long periods.
Elevated levels of cardiac troponin signal an increased risk of cardiovascular events even when the cause of that elevation is unknown, suggests a study published in the Journal of the American College of Cardiology.